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NEW SAFETY INFORMATION ON AZITHROMYCIN 
In the last few years the scientific community was debating the safety of the widely used macrolide antibiotic, azithromycin, which is commonly prescribed for respiratory and urinary tract infections. 
Previously published observational studies examined the 
risk of cardiovascular outcomes with azithromycin use, but these 
studies had conflicting results. The first such study to be published, 
a cohort study using U.S. Medicaid data, found an increased risk of 
cardiovascular death with azithromycin use. This led the Food and 
Drug Association to issue a warning on the safety of azithromycin 
use, although the European Medicines Agency did not take a position 
on this issue. Subsequent studies, both in the U.S. and in Europe 
did not always observe a risk of cardiovascular adverse events. This 
was likely due to several factors. Some studies investigated the link 
between cardiovascular death and azithromycin use. However, 
cardiovascular death can be considered a rather ambiguous outcome 
.given that the concern with aZithromycin use should be ventricular 
arrhythmia specifically, based on the effect of macrolides on QT-
interval prolongation. Cardiovascular death may be due to conditions 
unrelated to ventricular arrhythmia. It is therefore possible that the 
cardiovascular impact of azithromycin is over-estimated by using this 
general clinical outcome. Another important factor leading to variation 
among the published studies is the diversity in the underlying study 
populations. For example, a study conducted among persons with a 
lower socioeconomic status such as Medicaid beneficiaries may show a 
comparatively higher cardiovascular risk than a European population. 
In order to extensively investigate the cardiovascular risk of 
azithromycin in a European population, a recently published studyI 
investigated the risk of ventricular arrhythmia with azithromycin use in 
five European countries, i.e. Denmark, Italy, Germany, the Netherlands 
HEPATITIS 
Hepatitis can be defined in simple terms as an inflanlmation of the liver. There are various causes of hepatitis; the most common are viral infections (Hepatitis A, B and C) and 
Alcoholic Hepatitis. While these causes all result in liver damage, 
it is important to note that these diseases are distinct from each 
other and have different symptoms, treatments and risk factors. 
Hepatitis A is caused by the Hepatitis A virus (HAV). This 
virus is transmitted mainly tllrough food and water contaminated 
with the faeces of an infected person. Poor sanitation and lack of 
clean water are the two main risk factors for Hepatitis A. Hepatitis 
A causes acute liver failure and generally isn't fatal. 
Hepatitis B is caused by the Hepatitis B virus and is spread 
by contact with blood or other bodily fluids of infected persons. 
Hepatitis B can cause both chronic and acute liver failure and 
can be rapidly fatal. 
Hepatitis C is caused by the Hepatitis C virus. This particular 
virus is blood-borne, those most at risk of developing Hepatitis 
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and UK, using a common methodology applied to seven healthcare 
databases. This allowed the researchers to reach a very large study sample 
of over 14 million new antibiotic users. The results of this study, published 
last April in the Canadian Medical Journal indicate a higher risk of 
ventricular arrhythmia in azithromycin users when compared to non-
users of antibiotics, but no excess risk compared to the use of amoxicillin, 
a widely used antibiotic not considered to be associated witll any 
cardiovascular events. These findings suggest that the risk of ventricular 
arrhythmia with azithromycin use is likely to be mainly due to the poor 
state of health from the underlying infection rather than the drug itself. 
The primary analyses from the single databases were robustly tested 
through meta-analysis of the pooled risk estimates obtained from all the 
databases together, confirming the findings of the primary analysis. !< 
The referenced article is freely available from the Canadian Medical Journal 
website, i.e. http://www.cmaj.ca/content/ 189115/E560full.pdf+html. 
The principal investigator of the study, Pro! Gianluca Trifiro', leads a 
pharmacoepidemiology research team based in Messina. Dr Janet Sultana 
was one of the CO-investigators and is a Maltese joint post-doctoral researcher 
at the University of Messina and the Erasmus Medical Centre, working in his 
team based in Sicily. She can be contacted on jaysultana@gmail.com. 
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C are IV drug users who partake in the sharing of needles. 
Hepatitis C can cause both acute and chronic liver failure. 
Alcoholic Hepatitis is caused by sustained excessive 
alcohol intake over a period of years. Symptoms include 
jaundice and abdominal distention due to fluid build-up. 
Alcoholic Hepatitis usually leads to chronic liver failure. Liver 
Cirrhosis is also commonly observed in patients suffering 
from Alcoholic Hepatitis. 
There are vaccines available that can easily prevent 
Hepatitis A and B. There is no vaccine available for Hepatitis C 
and Alcoholic Hepatitis but taking simple precautions such as 
limiting alcohol intake and safe handling of needles can help 
prevent these diseases. 
Every year WHO organizes World Hepatitis Day on the 28 
July in order to increase awareness about the disease. X 
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